Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

Dyax, Kadmon ink library license agreement
September 2011
SHARING OPTIONS:

CAMBRIDGE, Mass.Dyax Corp. recently granted Kadmon Corp. LLC a non-exclusive license to its proprietary "gold-standard" antibody phage display libraries for the discovery and development of therapeutic antibodies. The libraries combine gene fragments from human donors with strategically designed synthetic DNA and are utilized in the identification of high-affinity human antibodies that bind to numerous therapeutic targets, including cell surface proteins such as tumor cell markers, enzymes, viral antigens and glycoproteins. The strategic agreement includes upfront and annual license fees as well as clinical and regulatory milestone payments. In addition, Dyax is entitled to royalties on net sales of any products identified that Kadmon might develop and commercialize using Dyax's technology. Kadmon also gains sublicenses to relevant third-party antibody phage display patents that relate to Dyax's technology.


Back


PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.